Cart
sales@molnova.com
A-794282
CAS No. 869802-44-8
A-794282( —— )
Catalog No. M34148 CAS No. 869802-44-8
A-794282 is a selective and potent mGlu1 receptor antagonist with analgesic activity and may be useful in the study of neurologic disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 411 | In Stock |
|
| 10MG | 562 | In Stock |
|
| 25MG | 866 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1469 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameA-794282
-
NoteResearch use only, not for human use.
-
Brief DescriptionA-794282 is a selective and potent mGlu1 receptor antagonist with analgesic activity and may be useful in the study of neurologic disorders.
-
DescriptionA-794282 is a selective and potent mGlu1 receptor antagonist with analgesic activity and may be useful in the study of neurologic disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number869802-44-8
-
Formula Weight350.44
-
Molecular FormulaC19H18N4OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=2SC3=NC=CC(=C3C2N=CN1C4=CC=C(C=C4)CC)N(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
YM90K hydrochloride
YM90K hydrochloride is an antagonist of AMPA receptor.
-
HBT1
HBT1 is an AMPA receptor potentiator that induces production of brain-derived neurotrophic factor (BDNF) and exhibits little agonistic effect in primary neurons. HBT1 binds to ligand-binding domain of AMPA-R in glutamate dependent manner.HBT1 bound to the ligand-binding domain (LBD) of AMPA-R in a glutamate-dependent manner.?
-
1-ethyl-3-morpholin-...
1-ethyl-3-morpholin-4-yl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile is a positive allosteric modulator of mGluR3 and can be used in studies about the treatment of Parkinson's disease.
